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AbstrAct
Aims. To compare 1p/19q codeletion, MGMT promoter methylation, and IDH mutation status in stereotactic biopsy and open 
craniotomy specimens. 
clinical rationale. The latest WHO classification of gliomas requires assessment of the expression of molecular markers. 
Samples can be obtained for molecular assays via open craniotomy or molecular stereotactic biopsy (MSB). However, there is 
uncertainty as to whether MSB is representative of the entire tumour, and therefore how reliable it is for treatment planning. 
Patients and methods. We examined 11 patients diagnosed with brain tumours suspicious of glioma who underwent open cra-
niotomy after stereotactic biopsy and in whom multiple biomarkers were assessed in both sets of samples by methylation-spe-
cific multiplex ligation-dependent probe amplification.  Institutional Review Board ethical approval was granted (KB 694/2018).
results. The initial histopathological grade as determined by stereotactic biopsy was the same as in the samples obtained by 
open surgery. Further, the marker profile used here was valid in both high- and low-grade gliomas. 
conclusion and clinical implication. MSB is a reliable way to obtain material for precision medicine approaches.
Key words: 1p/19q codeletion; glioma; IDH; methylation-specific multiplex ligation-dependent probe amplification; MGMT; 
stereotactic biopsy
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Introduction
Gliomas are the most common primary malignant in-
tracranial tumour, with an annual incidence of ~5 cases per 
100,000 people [1–6]. In addition to the patient’s performance 
status at the time of diagnosis, the main prognostic factor for 
glioma is the presence/absence of some common biomark-
ers: (i) methylation of the promoter of the gene encoding 
the enzyme O-6-methylguanine-DNA methyltransferase 
(MGMT); (ii) isocitrate dehydrogenase 1 (IDH1) mutations; 
(iii) isocitrate dehydrogenase 2 (IDH2) mutations; and (iv)
chromosome 1p/19q codeletion. These molecular tests are
diagnostic, prognostic, clinical manifestations and, in some 
cases, predictive of responses to different therapies [7–11]. 
IDH1 and IDH2 mutations are useful in the assessment of 
primary and secondary gliomas and, if present, indicate at 
least WHO grade II glioma [12]. 1p/19q codeletion supports 
the diagnosis of oligodendroglioma/oligoastrocytoma [13, 
14], occurring in ~75% of oligodendrogliomas and ~45% 
of oligoastrocytomas but seldom in fibrillary astrocytomas 
(~8 %) [14, 15]. Molecular testing alters the diagnosis in about 
3% of cases [16].
However, tumour heterogeneity may also influence the 
detection and value of these biomarkers [17]. 1p/19q deletions, 
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MGMT methylation, and IDH mutations can all show hetero-
geneity in individual tumours, thereby limiting the routine 
implementation of these molecular results derived from 
biopsies in clinical practice [17]. 
Clinical rationale 
Molecular stereotactic biopsy (MSB) of untreated gliomas 
may improve diagnostic precision and enable personalised 
treatment in inoperable patients. However, glioma heterogene-
ity and limited cell numbers in small MSB biopsy samples can 
give rise to diagnostic errors. Therefore, the aim of this study 
was to compare the molecular results derived from MSBs to 
those in open craniotomy specimens. 
Materials and methods 
Patients, consent, and ethics
The Department of Neurosurgery at the 10th Military 
Research Hospital (Bydgoszcz, Poland) has conducted over 
2,500 stereotactic biopsies of brain tumours since 1996. MSB 
has been performed since 2014. Here, we retrospectively ana-
lysed data from a database of 485 patients undergoing MSB. 
MSB was performed when: (1) primary tumours and 
recurrences were located within areas of increased risk of 
comorbidity without severe mass effect demanding debulking 
surgery because of brainstem compression and/or midline 
shift; (2) patients had Karnofsky performance status (KPS) 
<60; and (3) inflammation or lymphoma was suspected. Open 
craniotomy was performed after MSB when radiology and 
biopsy results were equivocal. 
The xxx Institutional Review Board (KB 694/2018) re-
viewed and approved the study protocol, which was conducted 
according to the principles of the Declaration of Helsinki.
Biopsy and surgery procedures
CT brain scans were performed after fixation of the ste-
reotactic frame to the head on the day of surgery. CT images 
were co-registered with preoperative MRI scans. Patients were 
consented and operated upon by a neurosurgeon who, based 
on the imaging results and clinical features, developed the 
biopsy trajectory using iPlan software (BrainLAB, Germany) 
(Fig. 1A). Biopsy needles were inserted, and serial samples 
were obtained every 1 mm using microforceps from contrast-
enhancing parts of the tumour. 
For MSB, the first biopsy sample was stained with methy-
lene blue for intraoperative histopathological examination. 
The neuropathologist classified samples according to the 
World Health Organisation (WHO) criteria [18]. Every second 
sample was taken for histopathology assessment and immuno-
histochemistry as necessary. The same sample was examined 
by methylation-specific (MS-) multiplex ligation-dependent 
probe amplification (MLPA) for molecular alterations (see 
below). The sample intraoperatively assessed as the largest (on 
average 50 cells) was selected for molecular testing. 
During craniotomy, samples for molecular and histopatho-
logical assessment were chosen arbitrarily by the neurosurgeon 
based on macroscopic evaluation (e.g. highly vascularised 
areas), and radiological changes visualised by MRI used for 
neuronavigation +/- application of 5-ALA fluorescence marker 
(Fig. 2). Tumour samples for postoperative molecular exami-
nation were much larger than those taken for intraoperative 
biopsy. After surgery, MRI was used to assess the resection sta-
tus using a 3T (Philips) device, T1 and T2 sequences, and after 
intravenous administration of gadobutrol contrast medium 
(1 mmol/ml) at a dose of 0.1 ml/kg body weight [19] (Fig. 1B).
Molecular analysis
MS-MLPA allows simultaneous analysis of multiple mo-
lecular markers using small amounts (100 ng) of DNA isolated 
Figure 1. A. biopsy planning based on T2-Flair MRI (patient 2). B. Post surgery T2-Flair MRI (patient 2) 
A b
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Figure 2. A. Tumour in 5-ALA induced fluorescence (patient 9). B. Tumour in white light (patient 9)
A b
from paraffin-embedded tissue. The MS-MLPA method is 
described in detail elsewhere [20]. Briefly, DNA was extracted 
from the fixed samples by the magnetic method using a Max-
well® 16 FFPE Tissue LEV DNA Purification Kit (Promega, 
Madison, WI, USA). The MLPA method was validated prior 
to clinical use on 50 archival tissue samples, with methylation 
verified using pyrosequencing and methylation PCR. Co-
deletion was not verified using other methods because there 
is known to be a high correlation between MLPA and FISH 
test results [21–23].
MLPA is a comparative method, i.e. the result of a given 
test sample is compared to a control. According to the manu-
facturer’s recommendations (MRC, Holland), for each experi-
ment a minimum of four reference tests was used when the 
number of test samples did not exceed 20; when there were 
> 20 tests performed, one reference sample was added for every 
seven tests in accordance with the manufacturer’s recommen-
dations. In addition, MLPA has a number of internal controls 
to assess each reaction and the purity and amount of DNA. 
The results were analysed using the dedicated coffalyser.net 
software (MRC, Holland). Repeatability and reproducibility 
were established as 100%.
Statistical analysis
The results were described using descriptive statistics. 
Cohen’s kappa coefficient and intraclass correlation coefficient 
(ICC) was used to assess the agreement between MSB and open 
biopsy molecular results (Statistica v 13.0).  
Results
Of 531 patients with molecular results, only 11 (2.1%) 
patients had molecular tests from both the MSB and subse-
quent surgery; five women (45.5%) and six men (Table 1). The 
median age was 35 years (IQR 21–60 years). The initial KPS 
ranged from 60 to 100. After treatment, two patients experi-
enced a deterioration in their quality of life. 
Only one case had been biopsied and diagnosed as a glioma 
prior to surgery to determine the nature of the MRI changes. In 
this case, the MSB was performed to determine whether the vis-
ible lesion represented recurrence or necrosis after radiotherapy. 
In the MSBs, four (36.4%) patients had WHO II astrocytoma 
diffusum, one patient (9.1%) had oligodendroglioma, and the 
other six were classified as high-grade malignant gliomas. Of 
these, four (36.4%) were diagnosed with anaplastic astrocytoma, 
and two (18.2%) with glioblastoma multiforme. There were no 
other treatments between procedures, and the median interval 
between procedures was 57.5 days (16–132 days) (Tab. 1).
In all cases, the molecular tests were conclusive (Tab. 2). 
No perioperative complications were noted, and the neuro-
logical status did not change after MSB. After the procedure, 
each patient had a follow-up CT examination that did not 
reveal any bleeding. After surgery, the patients had a control 
MRI with contrast, which also showed no clinically significant 
incidents of bleeding. 
A total absence of contrast-enhancing lesion or a contrast-
enhancing lesion with < 2% of the baseline change was consid-
ered to be a complete tumour resection. Contrast-enhancing 
lesions with a volume > 2% of the initial change were con-
sidered partial resections. In the post-surgery MRIs, total 
resection was demonstrated in seven (63.6%) cases and partial 
resection in four cases (36.4%) (Tab. 2). Two patients expe-
rienced a deterioration in neurological status accompanied 
by a deterioration in quality of life after craniotomy (18.2%). 
All histopathological findings after craniotomies were the 
same as the MSB results. The molecular results were also the same 
in all cases (absolute agreement of 1.00 ICC). MGMT promoter 
methylation was present in two patients, and IDH mutations were 
present in seven cases (Cohen’s kappa coefficient 1, p < 0.05).
Discussion
Here we report that molecular genetics results derived 
from MSB are reliable and representative of both low- and 
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table 1. Clinicopathological features of the study population
Variable Value
Age Median 35 years (IQR 21–60 years)
Gender Female 5 (45.5%)
Male 6 (54.5%)
KPS before resection of a tumour 100 7 (63.6%)
 90 2 (18.2%)
 80 1 (9.1%)
 70 0 (0%)
 60 1 (9.1%)
KPS after resection of a tumour 100 6 (54%)
 90 2 (18.2%)
 80 0 (0%)
 70 2 (18.2%)
 60 1 (9.1%)
Performance status deterioration after surgery 2 (18.2%)
Histopathological diagnosis Astrocytoma WHO II 4 (36.4%)
 Oligodendroglioma WHO II 1 (9.1%)
 Astrocytoma anaplasticum WHO III 4 (36.4%)
 GBM WHO IV 2 (18.2%)
Interval between biopsy and resection Median 57 days (range 16–132 days)
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high-grade gliomas. MLPA testing on stereotactic biopsy 
material and tissue derived after craniotomy appears to be 
equivalent for genetic analysis. 
Molecular diagnostic testing should be considered when-
ever changes in tumour molecular biology might be expected, 
i.e. after primary therapy and where the results might justify 
the use of adjuvant systemic therapy. At the time of asymp-
tomatic recurrence, the value of an open craniotomy should 
be balanced against the risk of complications and prolonging 
the time before starting systemic or radiation therapy [24–28]. 
Additionally, safe resection or macroscopic tumour removal 
is not feasible when gliomas are localised in eloquent areas. 
The role of subtotal surgery, especially in recurrent high-grade 
gliomas or previously unirradiated low-grade gliomas, remains 
unclear. It has been shown that subtotal tumour removal has 
no advantage over chemoradiation in the treatment of glio-
blastomas. Nevertheless, partial resections have generally been 
considered to be the only reliable method to obtain precise 
molecular results, and from this point of view our results are 
of great practical significance.
The simultaneous development of molecular diagnostics 
and the possibility of adopting effective conservative treatment 
in patients with low-grade gliomas with IDH1 mutations en-
courages the use of MSB [29, 30]. Our data suggests that it is 
reasonable to guide targeted therapies based on MSB results 
rather than open surgery. The most beneficial genetic alteration 
in gliomas is coexistent IDH1 mutation and MGMT promoter 
methylation [31]. Here, both IDH mutation and MGMT pro-
moter methylation status established by MSB and surgery were 
conclusive, irrespective of tumour grade.
In a recent report, macroscopic gross total resection was 
achieved in approximately 80% of glioma cases [32]. In patients 
initially qualifying for stereotactic biopsy, complete surgical 
resection was more difficult, being achieved in 63.6% of cases, 
and as a consequence of preselection of patients for MSB in 
our department.
In this study, MS-MLPA was used due to its high reproduc-
ibility, accuracy, and robustness [20-23, 33]. MS-MLPA has 
a number of advantages over conventional MS-polymerase 
chain reaction (PCR) [20]. Regardless of the method used, it 
should be emphasised that MGMT promoter methylation may 
change over time [34, 35], which must be taken into account 
when there is a long gap between examinations.
Glioma heterogeneity has been evaluated in several stud-
ies [36–41]. Heterogeneous MGMT promoter methylation 
status has mainly been noted in high-grade tumours [42, 
43], raising concerns as to whether single MSB results are 
representative. Some studies have reported differences in 
the molecular and histopathological diagnosis in different 
samples from the same tumour, missing anaplastic foci in 
stereotactic samples [39, 44]. Furthermore, the phenomenon 
of pseudo-heterogeneity should be considered when there 
are large amounts of intratumoural necrosis, inflamma-
tion, or normal tissue in glioma samples. A recent study 
[38] detected no MGMT promoter heterogeneity between 
different samples taken from the same tumours in 24 out 
of 25 patients; the one false negative that was detected was 
due to DNA dispersing into necrotic tissues. This is consis-
tent with our results and the results of a serial MSB study 
into WHO II gliomas, where MGMT methylation and IDH 
mutations were homogeneous inside and outside hotspots 
of all 14 tumours tested [44].
A recent comparison of biopsy and surgery molecular 
results [45] reported similar results to ours, the main differ-
ences being the histopathological diagnosis and molecular 
diagnostic test (MS-PCR) chosen [16]. Gessler et al. [45] 
did not examine low-grade gliomas, the group instead being 
limited to three anaplastic astrocytomas and 19 glioblasto-
mas. In both studies, samples were examined after a short 
interval, mainly due to the non-specific radiological appear-
ances. Conclusive molecular biomarkers were obtained from 
small biopsy samples (< 1 mm3) by selecting many probes 
and by using a highly controlled sampling technique, with 
intraoperative neuropathological examination to exclude any 
contamination. Eigenbrod et al. [16] collected at least two 
samples from different tumour sites to determine MGMT 
promoter methylation, while we showed that the results are 
the same in samples obtained by biopsy and open craniotomy. 
We also showed that MSB is effective in both low- and high-
grade gliomas.
Many papers have reported the safety and diagnostic value 
of materials obtained using stereotactic biopsy [46–50]. The 
number of perioperative complications occurring during 
surgical resections of brain tumours remains significant [51]. 
Even in our neurosurgery department, a facility with a high 
level of experience, the performance status decreased in two 
out of 11 patients. 
Our study is limited by the small number of cases analysed; 
however, this also meant that of 531 biopsies, only 11 had clini-
cal indications for subsequent open surgery. This uncommon 
scenario is also reflected in the number of patients recruited 
in other series [45]. It should be noted that the proportion 
of normal, non-tumour cells and neoplastic cells may falsely 
influence the MGMT methylation result in MS-MLPA. Mo-
reover,  there was an almost two month gap between MSB and 
open craniotomy in some cases, although histopathological 
and molecular results did not change depite this interval.
Clinical implications/future directions
Given our small group, cautious conclusions should be 
drawn. However, we have shown that the material obtained 
for MSB from both low- and high-grade gliomas can be used 
for the precise assessment of molecular status, and that MSB 
provides material for the valid and reproducible examination 
for multiple biomarkers without compromising the quality of 
histological classification and grading. MSB can be used for 
definitive molecular diagnosis and represents the final stage 
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of neurosurgical activities in some cases, especially tumours 
in which there is little chance of total removal without conse-
quential neurological deficits. Further large-scale concordance 
studies are required to further validate molecular diagnoses 
on MSB specimens. 
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